MAIA Biotechnology, Inc. (MAIA) Insider Trading & SEC Filings

Updated Jul 16, 2026 · Last SEC filing 2026-07-02

MAIA Biotechnology, Inc. (MAIA) has filed 12 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-07-02. 2 Form 8-K material event filings were reported by MAIA in the last 90 days. InsiderAlpha tracks every MAIA SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.

About MAIA Biotechnology, Inc. (MAIA)

SIC classification	Pharmaceutical Preparations (SIC 2834)
SEC CIK	0001878313

90-Day SEC Filing Activity

Form 4 filings (90d)	12
Form 8-K filings (90d)	2
Latest Form 4 filing	2026-07-02

Recent MAIA Insider Transactions (Form 4)

Date	Insider	Role	Transaction	Shares	Price	Value	Filing
2026-06-01	Vitoc Vlad	Chief Executive Officer	P — Open-market purchase	72.7K	$1.39	$101K	SEC
2026-06-01	Gryaznov Sergei	Chief Scientific Officer	P — Open-market purchase	2.0K	$1.34	$3K	SEC
2026-06-01	Smith Stan	Director	P — Open-market purchase	75.0K	$1.34	$100K	SEC
2025-12-22	CHAOUKI STEVEN M	Director	P — Open-market purchase	40.8K	$1.22	$50K	SEC
2025-12-22	Louie Ngar Yee	Director	P — Open-market purchase	81.7K	$1.22	$100K	SEC
2025-12-22	Smith Stan	Director	P — Open-market purchase	57.2K	$1.22	$70K	SEC
2025-10-01	Smith Stan	Director	P — Open-market purchase	19.2K	$1.30	$25K	SEC
2024-12-13	Smith Stan	Director	P — Open-market purchase	25.0K	$1.87	$47K	SEC
2024-12-13	Guerrero Ramiro	Director	P — Open-market purchase	53.4K	$1.87	$100K	SEC
2024-11-01	CHAOUKI STEVEN M	Director	P — Open-market purchase	22.1K	$2.51	$56K	SEC
2024-11-01	Smith Stan	Director	P — Open-market purchase	100.0K	$2.51	$251K	SEC
2024-11-01	Luput Cristian	Director	P — Open-market purchase	22.1K	$2.51	$56K	SEC
2024-11-01	Guerrero Ramiro	Director	P — Open-market purchase	88.5K	$2.51	$222K	SEC
2024-05-01	Smith Stan	Director	G — Bona-fide gift	20.0K	$0.00	—	SEC
2022-09-19	Smith Stan	Director	P — Open-market purchase	2.7K	$3.69	$10K	SEC

All transactions sourced from SEC EDGAR Form 4 filings for MAIA Biotechnology, Inc. (MAIA). Updated in real time as new filings are submitted to the SEC.

Most-Active MAIA Insiders — Last 90 Days

Insider	Form 4 filings	Total transaction value
Vitoc Vlad	2	$101K
Gryaznov Sergei	2	$3K
Smith Stan	2	$100K
Luput Cristian	1	—
Theagene Jean-Manasse	1	—

Recent MAIA Form 8-K Material Events

2026-05-22 — Item 5.07 [SEC]
2026-05-14 — Item 1.02 [SEC]
2026-04-16 — Item 8.01, 9.01 · Clinical · positive [SEC]
MAIA Biotechnology announced the activation of the first U.S. site for an ongoing international Phase 2 expansion trial of its novel telomere-targeting treatment for advanced non-small cell lung cancer. This represents a key milestone in the company's clinical development program
2026-04-08 — Item 8.01, 9.01 · Financing · positive [SEC]
MAIA Biotechnology announced a recent $33 million capital raise that the company expects will fully fund its ongoing pivotal Phase 3 trial of a novel telomere-targeting anticancer therapy. The financing provides runway certainty for the company's lead clinical program.
2026-04-02 — Item 5.02, 9.01 · Leadership · neutral [SEC]
MAIA Biotechnology's Board approved one-time bonus payments to CEO Vlad Vitoc ($312,610) and Head of Finance Jeffrey Himmelreich ($50,000) in recognition of their efforts on a recent capital raise. The bonuses were paid on March 31, 2026.

Recent Insider Filings

2026-07-02 — CHAOUKI STEVEN M (Director)
2026-07-02 — Guerrero Ramiro (Director)
2026-07-02 — Louie Ngar Yee (Director)
2026-07-02 — Luput Cristian (Director)
2026-07-02 — Smith Stan (Director)

Form 4 Transaction Code Reference

SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in MAIA insider filings:

P	Open-market purchase by the insider
S	Open-market sale by the insider
A	Grant, award, or other acquisition from the issuer
M	Exercise or conversion of derivative security (e.g. options)
F	Payment of exercise price or tax liability via share withholding
G	Bona-fide gift of securities
D	Disposition to the issuer (e.g. share buyback participation)
J	Other acquisition or disposition
X	Exercise of in-the-money or at-the-money derivative security
C	Conversion of derivative security
V	Transaction voluntarily reported earlier than required

MAIA Insider Trading — FAQ

What is the latest insider trade for MAIA?: MAIA Biotechnology, Inc. (MAIA) had 12 insider filings in the last 90 days, with the most recent on 2026-07-02. InsiderAlpha tracks every Form 4, 10-K, 10-Q, and 8-K filing in real time.
How many insiders are buying MAIA stock?: 0 insider purchases of MAIA were filed in the last 90 days.
How many insiders are selling MAIA stock?: 0 insider sales of MAIA were filed in the last 90 days.
Where can I see MAIA SEC filings (Form 4, 10-K, 10-Q, 8-K)?: InsiderAlpha aggregates every MAIA SEC filing — Form 4 insider transactions, 10-K and 10-Q quarterly reports, and 8-K material event disclosures — in one timeline.

Related Companies — Recent Insider Activity

Learn More

Open the live MAIA dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.